ArticleAntimicrobial agents and chemotherapy2011
CMX001 potentiates the efficacy of acyclovir in herpes simplex virus infections.
Article in Antimicrobial agents and chemotherapy, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 58 citations in OpenAlex.
- Herpes Simplex Encephalitis: Lack of Clinical Benefit of Long-term Valacyclovir Therapy.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2015Trial
- Article
- Herpes Simplex Virus, Human Papillomavirus, and Cervical Cancer: Overview, Relationship, and Treatment Implications.Cancers · 2023Review
- Review
- Antiviral activity of triptolide on herpes simplex virus in vitro.Immunity, inflammation and disease · 2022Article
- Cepharanthine Suppresses Herpes Simplex Virus Type 1 Replication Through the Downregulation of the PI3K/Akt and p38 MAPK Signaling Pathways.Frontiers in microbiology · 2021Article
- Immunomodulatory Strategies in Herpes Simplex Virus Encephalitis.Clinical microbiology reviews · 2020Review
- Current Antivirals and Novel Botanical Molecules Interfering With Herpes Simplex Virus Infection.Frontiers in microbiology · 2020Review
- Antiviral Therapies for Herpesviruses: Current Agents and New Directions.Clinical therapeutics · 2018Review
- Brincidofovir (CMX001) Toxicity Associated With Epithelial Apoptosis and Crypt Drop Out in a Hematopoietic Cell Transplant Patient: Challenges in Distinguishing Drug Toxicity From GVHD.Journal of pediatric hematology/oncology · 2018Article
- Efficacy of pritelivir and acyclovir in the treatment of herpes simplex virus infections in a mouse model of herpes simplex encephalitis.Antiviral research · 2018Article
- Comparison of three dimensional synergistic analyses of percentage versus logarithmic data in antiviral studies.Antiviral research · 2017Article
- Herpes Simplex Encephalitis: an Update.Current infectious disease reports · 2017Review
- TAOK3 phosphorylates the methylenecyclopropane nucleoside MBX 2168 to its monophosphate.Antiviral research · 2015Article
- Inhibition of LSD1 reduces herpesvirus infection, shedding, and recurrence by promoting epigenetic suppression of viral genomes.Science translational medicine · 2014Article
- Conformational analysis, molecular structure and solid state simulation of the antiviral drug acyclovir (zovirax) using density functional theory methods.Pharmaceuticals (Basel, Switzerland) · 2014Article
- Update on emerging antivirals for the management of herpes simplex virus infections: a patenting perspective.Recent patents on anti-infective drug discovery · 2013Review
- Article
- Molecular diagnosis and management of viral infections in hematopoietic stem cell transplant recipients.Molecular diagnosis & therapy · 2012Review
- Progress in the development of new therapies for herpesvirus infections.Current opinion in virology · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
Abstract
Although acyclovir (ACV) has proven to be of value in the therapy of certain herpes simplex virus (HSV) infections, there is a need for more effective therapies, particularly for serious infections in neonates and immunocompromised individuals, where resistance to this drug can be problematic. CMX001 is an orally bioavailable lipid conjugate of cidofovir that is substantially less nephrotoxic than the parent drug and has excellent antiviral activity against all the human herpesviruses. This compound retains full antiviral activity against ACV-resistant laboratory and clinical isolates. The combined efficacy of CMX001 and ACV was evaluated in a new real-time PCR combination assay, which demonstrated that the combination synergistically inhibited the replication of HSV in cell culture. This was also confirmed in murine models of HSV infection, where the combined therapy with these two drugs synergistically reduced mortality. These results suggest that CMX001 may be effective in the treatment of ACV-resistant HSV infections and as an adjunct therapy in individuals with suboptimal responses to ACV.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.